Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1540159/000165495421008915/edsa_10q.htm
May 2024
December 2023
October 2023
October 2023
October 2023
October 2023
August 2023
June 2023
June 2023
May 2023
|
Three Months Ended
|
Nine Months Ended
|
||
|
June 30, 2021
|
June 30, 2020
|
June 30, 2021
|
June 30, 2020
|
|
|
|
|
|
Total Revenues
|
$-
|
$109,985
|
$-
|
$328,301
|
|
|
|
|
|
Expenses:
|
|
|
|
|
Cost
of sales
|
-
|
1,472
|
-
|
15,287
|
Research
and development
|
4,464,347
|
1,143,868
|
13,819,305
|
2,174,680
|
General
and administrative
|
1,608,232
|
733,079
|
4,377,507
|
2,528,702
|
|
|
|
|
|
|
6,072,579
|
1,878,419
|
18,196,812
|
4,718,669
|
|
|
|
|
|
Loss from Operations
|
(6,072,579)
|
(1,768,434)
|
(18,196,812)
|
(4,390,368)
|
|
|
|
|
|
Other Income (Loss):
|
|
|
|
|
Reimbursement
grant income
|
1,306,796
|
-
|
8,477,261
|
-
|
Other
income (loss)
|
6,273
|
2,671
|
63,242
|
41,436
|
|
|
|
|
|
Loss before income taxes
|
(4,759,510)
|
(1,765,763)
|
(9,656,309)
|
(4,348,932)
|
|
|
|
|
|
Income tax expense
|
-
|
-
|
800
|
800
|
|
|
|
|
|
Net Loss
|
(4,759,510)
|
(1,765,763)
|
(9,657,109)
|
(4,349,732)
|
|
|
|
|
|
Exchange
differences on translation
|
174,128
|
68,972
|
267,075
|
47,178
|
|
|
|
|
|
Net Comprehensive Loss
|
$(4,585,382)
|
$(1,696,791)
|
$(9,390,034)
|
$(4,302,554)
|
|
|
|
|
|
Weighted
average number of common shares
|
13,251,999
|
8,859,520
|
11,680,294
|
8,364,866
|
|
|
|
|
|
Loss per common share - basic and diluted
|
$(0.36)
|
$(0.20)
|
$(0.83)
|
$(0.52)
|
|
June 30,
2021
|
September 30,
2020
|
|
|
|
Assets:
|
|
|
Cash
and cash equivalents
|
$8,052,574
|
$7,213,695
|
Other
current assets
|
6,281,733
|
890,323
|
Non-current
assets
|
2,543,036
|
2,658,357
|
|
|
|
Total Assets
|
$16,877,343
|
$10,762,375
|
|
|
|
Liabilities, shareholders' equity and temporary
equity:
|
|
|
Current
liabilities
|
$983,467
|
$1,529,857
|
Noncurrent
liabilities
|
90,121
|
124,388
|
Temporary
equity
|
-
|
2,476,955
|
Shareholders'
equity
|
15,803,755
|
6,631,175
|
|
|
|
Total liabilities, shareholders' equity and temporary
equity
|
$16,877,343
|
$10,762,375
|
|
Nine Months Ended
|
|
|
June 30, 2021
|
June 30, 2020
|
|
|
|
Cash flows from operating activities:
|
|
|
Net
loss
|
$(9,657,109)
|
$(4,349,732)
|
Adjustments
for noncash items
|
2,380,648
|
540,945
|
Change
in working capital items
|
(6,033,149)
|
495,384
|
|
|
|
Net cash used in operating activities
|
(13,309,610)
|
(3,313,403)
|
|
|
|
Net cash provided by (used in) investing activities
|
(7,610)
|
15,532
|
|
|
|
Net cash provided by financing activities
|
13,953,703
|
3,864,307
|
|
|
|
Effect
of exchange rate changes on cash and cash equivalents
|
202,396
|
43,676
|
|
|
|
Increase
in cash and cash equivalents during the period
|
838,879
|
610,112
|
Cash
and cash equivalents, beginning of period
|
7,213,695
|
5,030,583
|
|
|
|
Cash and cash equivalents, end of period
|
$8,052,574
|
$5,640,695
|
Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1540159/000165495421008915/edsa_10q.htm
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Edesa Biotech, Inc..
Edesa Biotech, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes:
Rating
Learn More
Since EB05 has demonstrated the ability to block signaling irrespective of the presence or concentration of the various molecules that frequently bind with TLR4, we believe that EB05 could ameliorate TLR4-mediated inflammation cascades in ARDS patients, thereby reducing lung injury, ventilation rates and mortality.
Research and development expenses increased by $3.32 million to $4.46 million for the three months ended June 30, 2021 compared to $1.14 million for the same period last year primarily due to increased external research expenses related to recruitment and enrollment in our ongoing clinical studies, increased investigational drug product expenses and an increase in noncash share-based compensation.
Research and development expenses increased by $11.65 million to $13.82 million for the nine months ended June 30, 2021 compared to $2.17 million for the same period last year primarily due to milestone payments related to advancement of our EB05 clinical program, increased external research expenses related to accelerated activity in our ongoing clinical studies, increased investigational drug product expenses and an increase in noncash share-based compensation.
The increase was primarily due to milestone payments related to advancement of our EB05 clinical program, increased external research expenses related to accelerated activity in our ongoing clinical studies, increased investigational drug product expenses and an increase in non-cash share-based compensation.
19 Total operating expenses increased by $4.19 million to $6.07 million for the three months ended June 30, 2021 compared to $1.88 million for the same period last year: There was no cost of sales for the three months ended June 30, 2021 compared to less than $0.01 million for the three months ended June 30, 2020, reflecting the winddown and discontinuation of sales of product inventory from legacy operations.
Total operating expenses increased by...Read more
When used in this report,...Read more
General and administrative expenses increased...Read more
General and administrative expenses increased...Read more
If we determine it is...Read more
Our research and development expenses...Read more
Although we believe the expectations...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-Q Quarterly Report
Material Contracts, Statements, Certifications & more
Edesa Biotech, Inc. provided additional information to their SEC Filing as exhibits
Ticker: EDSA
CIK: 1540159
Form Type: 10-Q Quarterly Report
Accession Number: 0001654954-21-008915
Submitted to the SEC: Fri Aug 13 2021 4:16:33 PM EST
Accepted by the SEC: Fri Aug 13 2021
Period: Wednesday, June 30, 2021
Industry: Pharmaceutical Preparations